Dr Reddy's launches Cinacalcet tablets in US market
The newly launched product is a therapeutic equivalent generic version of Sensipar tablets, approved by the US Food and Drug Administration (USFDA), the Hyderabad-based drug firm said in a regulatory filing. Quoting IQVIA Health data, Dr Reddy's Laboratories said the Sensipar brand and generic market had the US sales of approximately USD 312 million for the most recent twelve months ending July 2020.
- Country:
- India
Dr Reddy's Laboratories on Thursday said it has launched Cinacalcet tablets, indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis, in the US market. The newly launched product is a therapeutic equivalent generic version of Sensipar tablets, approved by the US Food and Drug Administration (USFDA), the Hyderabad-based drug firm said in a regulatory filing.
Quoting IQVIA Health data, Dr Reddy's Laboratories said the Sensipar brand and generic market had the US sales of approximately USD 312 million for the most recent twelve months ending July 2020. Shares of Dr Reddy's Laboratories were trading 1.25 per cent lower at Rs 5,122 apiece on BSE.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Germany fully backs submarine negotiations with India, wants to offer military cooperation alternatives to New Delhi: German envoy
G-SHOCK Debuts Flagship Store in New Delhi, Setting New Trends in India's Capital City
Candidacy from New Delhi seat responsibility not reward: BJP's Bansuri Swaraj
28 bikes impounded in rash driving case in New Delhi area
New Delhi: Radiation therapy facility started in Lady Hardinge Hospital